Andrew Cheng - Aug 3, 2021 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Signature
/s/ Jonathan Young, Attorney-in-Fact
Stock symbol
AKRO
Transactions as of
Aug 3, 2021
Transactions value $
-$364,577
Form type
4
Date filed
8/4/2021, 05:38 PM
Previous filing
Jul 6, 2021
Next filing
Sep 3, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKRO Common Stock Sale -$352K -16.9K -4.92% $20.81 327K Aug 3, 2021 Direct F1, F2
transaction AKRO Common Stock Sale -$12.9K -600 -0.18% $21.48 326K Aug 3, 2021 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated May 26, 2021, previously adopted by the reporting person.
F2 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $20.43 to $21.22, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
F3 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $21.37 to $21.93, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.